Join Now

Category Archives: BioUtah News

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

By Natalie Themm | Published January 9, 2025

Denali expects to submit a Biologics License Application for tividenofusp alfa in early 2025 for regulatory review under the accelerated approval pathway

| Tagged | Comments Off on Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

By Natalie Themm | Published January 9, 2025

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

| Tagged | Comments Off on Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

By Natalie Themm | Published January 9, 2025

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

| Tagged | Comments Off on MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

M42’s IROS and Halia Therapeutics launch clinical study on obesity treatment in the UAE

By Natalie Themm | Published January 9, 2025

Trial underscores IROS’s commitment to developing innovative therapies for unmet medical needs

| Tagged | Comments Off on M42’s IROS and Halia Therapeutics launch clinical study on obesity treatment in the UAE

ARUP Offers New Assay To Detect Influenza A (H5) Virus

By admin | Published January 3, 2025

SALT LAKE CITY, January 3, 2025—ARUP Laboratories today launched a new assay for the detection and subtyping of influenza A (H5) virus. This test will aid in the evaluation of individuals who may have been exposed to highly pathogenic avian influenza (HPAI) A virus, also known as H5N1 or bird flu. In early 2024, an outbreak […]

| Comments Off on ARUP Offers New Assay To Detect Influenza A (H5) Virus

Sethera Therapeutics Completes First Funding Round

By Natalie Themm | Published January 2, 2025

Sethera Therapeutics Completes First Funding Round

| Tagged | Comments Off on Sethera Therapeutics Completes First Funding Round

Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis

By Natalie Themm | Published January 2, 2025

Data from Dual-Acting Oral Biologic Show Promising Safety and Efficacy Profile

| Tagged | Comments Off on Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis

CancerVax Passes First Test with Flying Colors

By Natalie Themm | Published January 2, 2025

Recent in-vitro lab results confirm that the Company’s Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells

| Tagged | Comments Off on CancerVax Passes First Test with Flying Colors

Merit Medical Announces FDA Approval of the WRAPSODY Cell-Impermeable Endoprosthesis

By Natalie Themm | Published January 2, 2025

Unique cell-impermeable1 design extends life-saving treatment for dialysis patients.

| Tagged | Comments Off on Merit Medical Announces FDA Approval of the WRAPSODY Cell-Impermeable Endoprosthesis

Here’s how Utah earned its No. 1 ranking for innovation

By Natalie Themm | Published December 19, 2024

A new report from the U.’s Kem C. Gardner Policy Institute uncovers the wide-ranging mechanisms driving Utah’s high performance when it comes to innovation output

| Comments Off on Here’s how Utah earned its No. 1 ranking for innovation

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

By Natalie Themm | Published December 19, 2024

Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinics. The program, launching this month, will run for a minimum of three years.

| Tagged | Comments Off on Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

By Natalie Themm | Published December 19, 2024

Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick Model

| Tagged | Comments Off on Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

A Special Thanks To Our Legacy and Platinum Elite Members